AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04111341 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: TCM Placebo 6g in the morning TCM Placebo 8g in the evening for 12 weeks
Study NCT02317640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Gel applied by a pump
Description: After being diagnosed with low testosterone levels the participant will be given a 30-day supply of the Testosterone/placebo gel (40.5 mg/day). The gel is to be applied every morning on clean and dry area of skin of the upper arms and shoulders.
Study NCT02317640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stand Training
Description: Stand training with BWST with manual assistance. Participant is placed on treadmill in an upright position and suspended in a harness by an overhead cable. A trainer will aid the participant in pelvis and trunk stabilization, by applying anterior forces at the pelvis and/or posterior forces at the shoulders and ensure that the trunk and pelvis are not flexed or hyper-extended.
Study NCT02317640 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stand Training
Description: Stand training with BWST with manual assistance. Participant is placed on treadmill in an upright position and suspended in a harness by an overhead cable. A trainer will aid the participant in pelvis and trunk stabilization, by applying anterior forces at the pelvis and/or posterior forces at the shoulders and ensure that the trunk and pelvis are not flexed or hyper-extended.
Study NCT02317640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation
Description: Electrical Stimulation (ES) will be applied via bifurcated leads and self-adhesive reusable surface electrodes. The electrodes will be applied over the motor points of both legs. Two electrodes will be used for contracting each muscle.
Study NCT01180075 — intervention group
Intervention type: DRUG
Intervention: tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV)
Description: Patients receiving this drug for clinical care at standard dosages will be enrolled.
Study NCT01180075 — intervention group
Intervention type: DRUG
Intervention: tenofovir/emtricitabine (TDF/FTC)
Description: Patients receiving this drug for clinical care at standard dosages will be enrolled.
Study NCT01180075 — intervention group
Intervention type: DRUG
Intervention: Atazanavir (ATV)
Description: Patients receiving this drug for clinical care at 300mg with 100mg ritonavir daily will be enrolled.
Study NCT01180075 — intervention group
Intervention type: DRUG
Intervention: Ritonavir
Description: Patients receiving this drug for clinical care at 100mg daily with 300mg atazanavir will be enrolled.
Study NCT01180075 — intervention group
Intervention type: PROCEDURE
Intervention: Phlebotomy
Description: Multiple blood draws will be performed in the study, and vary depending on the group.
Study NCT03717532 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be receiving blood flow restriction therapy with a pressure cuff set to a placebo pressure setting.
Study NCT03717532 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Personalized Tourniquet System for Blood Flow Restriction
Description: Patients will be receiving blood flow restriction therapy with a pressure cuff
Study NCT00403546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone 80-160 mg/d
Description: Participants will be instructed to take one study capsule of ziprasidone orally twice daily (80 mg/d). After the first week, the study drug will be increased to two capsules twice daily (160 mg/d).
Study NCT00403546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be instructed to take one study capsule of matching placebo orally twice daily. After the first week, the matching placebo will be increased to two capsules twice daily.
Study NCT00403546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone 160 mg/d
Description: Participants will be taking open-label ziprasidone 80 mg orally twice daily for a total dose of 160 mg/d from at least 3 weeks before randomization to end of study 8 weeks after randomization.
Study NCT00403546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ziprasidone 160 mg/d
Description: Participants will be taking open-label ziprasidone 80 mg orally twice daily for a total dose of 160 mg/d from at least 3 weeks before randomization to end of study 8 weeks after randomization.
Study NCT02243787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COVA322
Study NCT02243787 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03632161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: isobaric bupivacaine 0.5% (0.3ml/kg) and dexmedetomidine (1 mcg/kg)
Study NCT03632161 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine
Description: isobaric bupivacaine 0.5% (0.3ml/kg)
Study NCT01592630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Description: On-Q pumps containing 0.2% ropivacaine to be attached to TAP catheters
Study NCT01592630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: On-Q pumps containing saline to be attached to TAP catheters
Study NCT00354926 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AME-133v (LY2469298)
Description: IV 4X weekly X 4
Study NCT03503942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Description: Participants in the treatment arm will receive structured, locally tailored, group-based lifestyle interventions that consist of a core intervention phase (3 months) and a maintenance phase (33 months). The core intervention phase will consist of twice weekly group sessions on nutrition, exercise and goal-setting within the first 6 weeks followed by 6 weeks of self-directed lifestyle modification. During the maintenance phase, the participants will receive monthly short message service (SMS) on health tips as well as 6 monthly telephone calls from program coordinators.
Study NCT03503942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be will be prescribed to treatment group participants at highest risk of diabetes conversion (i.e.IFG + IGT or IFG + HbA1c ≥6.0%) after at least 6 months of lifestyle interventions at a starting dose of 250 mg twice a day followed by up-titration to 500 mg twice a day after 3 months if the participants do not experience any gastrointestinal side effects.
Study NCT03503942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: Participants will be given cash incentives if they meet the weight loss target, which is pre-defined as 5% of baseline weight, at the 3rd, 6th, 12th, 18th, 24th, 30th and 36th month of study period.
Study NCT00558675 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloStim
Description: single intravenous infusion of 1 x 10\^9 AlloStim cells
Study NCT00558675 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloStim
Description: Intravenous infusion of 1 x 10\^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10\^8 AlloStim on day 7
Study NCT00558675 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloStim
Description: Intravenous infusion of 1 x 10\^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10\^8 AlloStim on day 7 and day 14
Study NCT00558675 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloStim
Description: Intravenous infusion of 1 x 10\^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10\^8 AlloStim on day 7, day 14 and day 21
Study NCT01784705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial bright light therapy
Description: The bright light treatment was given transcranially via ear canals by using bright light device. The bright light was produced using two light-emitting diodes (LEDs). The bright light was transmitted into both ear canals by an optical fibre. Daily 12 minutes TBL was taken at home during forenoon.
Study NCT01784705 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial placebo treatment
Description: The placebo treatment was given transcranially via ear canals by placebo device. Daily 12 minutes placebo treatment was taken at home during forenoon.
Study NCT02316236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: an alpha-2 receptor agonist
Study NCT02316236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: loading dose
Description: 0.8ug/kg of dexmedetomidine is given in 10 minutes
Study NCT02316236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sustaining dose
Description: 0.4ug/kg/min of dexmedetomidine is given
Study NCT02480621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine with Bupivacaine
Description: Pain medications injected locally during surgery around affected ankle.
Study NCT03808285 — intervention group
Intervention type: OTHER
Intervention: mandibular osteomylitis
Study NCT01339650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-767
Description: ABT-767 once or twice daily for a 28 day cycle
Study NCT02405494 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Beverage 1
Study NCT02405494 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Beverage 2
Study NCT02405494 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Beverage 3
Study NCT02405494 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Beverage 4
Study NCT02405494 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Beverage 5
Study NCT02405494 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Beverage 6
Study NCT02405494 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Beverage 7
Study NCT02405494 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Beverage 8
Study NCT02405494 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Beverage 9
Study NCT01817764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umeclidinium/vilanterol
Description: Dry white powder delivered via NDPI (2 strips with 30 blisters each, first containing UMEC 62.5 mcg per blister and second containing VI 25 mcg per blister), administered as one inhalation of UMEC/VI 62.5/25 mcg once-daily in the morning
Study NCT01817764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate/salmeterol
Description: Dry white powder delivered via ACCUHALER/DISKUS (1 strip with 60 blisters, containing 250 mcg fluticasone propionate and 50 mcg salmeterol per blister), administered as one inhalation of FSC 250/50 mcg each morning and evening
Study NCT01817764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered via ACCUHALER/DISKUS or NDPI. Dry white powder administered as one inhalation each morning and evening via ACCUHALER/DISKUS (1 strip with 60 blisters containing placebo) OR once-daily in the morning via NDPI (2 strips with 30 blisters each, containing placebo)
Study NCT01817764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered via ACCUHALER/DISKUS or NDPI. Dry white powder administered as one inhalation each morning and evening via ACCUHALER/DISKUS (1 strip with 60 blisters containing placebo) OR once-daily in the morning via NDPI (2 strips with 30 blisters each, containing placebo)
Study NCT00788008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhalation anesthesia with isoflurane vs. TIVA with propofol
Description: variable depending upon patient
Study NCT01184781 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Comparison of capsule endoscopy Pillcam II™ versus colonoscopy
Description: On the same patient, we compare both methods (video-colonoscopy vs capsule endoscopy)
Study NCT03970252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT03970252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV
Study NCT03970252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT03970252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV
Study NCT03970252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT03970252 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03970252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT03950492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Simulator
Description: This is an open-label, safety, tolerability, and feasibility study for participants who have treatment refractory OUD that are eligible to have DBS targeting the NAc/VC.
Study NCT04670679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERAS-601
Description: Administered orally
Study NCT03970252 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT04670679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered via intravenous infusion
Study NCT01342367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Bicalutamide 50 mg orally daily with either dutasteride or finasteride for 2 months. After two months of treatment bicalutamide with either dutasteride or finasteride will be taken along with radiation. After completion of radiation, bicalutamide will be stopped.
Study NCT01342367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Description: Dutasteride 0.5 mg orally will be taken daily with bicalutamide for 2 months. After two months of treatment dutasteride and bicalutamide will be taken along with radiation. After completion of radiation, dutasteride will be taken alone for two years.
Study NCT01342367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride
Description: Finasteride 5 mg orally will be taken daily with bicalutamide for 2 months. After two months of treatment finasteride and bicalutamide will be taken along with radiation. After completion of radiation, finasteride will be taken alone for two years.
Study NCT01342367 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 7-8 weeks of radiation with bicalutamide and either dutasteride or finasteride.
Study NCT01527942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Intravenous Acetaminophen 1,000 mg IV
Study NCT01527942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - IV administration 0.9% 100 ml Sodium Chloride (NaCl)
Study NCT04670679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered via intravenous infusion
Study NCT02799082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: topical treatment for photodynamic therapy combining vehicle application and subsequent illumination with broad or narrow spectrum light sources (after 3 h of drug incubation).
Study NCT02799082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BF-200 ALA
Description: topical treatment for photodynamic therapy combining drug application and subsequent illumination with broad or narrow spectrum light sources (after 3 h of drug incubation).
Study NCT02621762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnesium
Description: Magnesium in dialysate increased
Study NCT02621762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bicarbonate
Description: Bicarbonate in dialysate increased
Study NCT01702233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traumeel S inj
Description: Traumeel S inj. 2 ml. subacromial 3 times at days 1, 8 and 15
Study NCT01702233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fortecortin/Dexamethasone 8 mg/2 ml inj
Description: Fortecortin/Dexamethasone 8 mg/2 ml inj. subacromial 3 times at days 1, 8 and 15
Study NCT01702233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline inj
Description: Saline inj. 2 ml. subacromial 3 times at days 1, 8 and 15
Study NCT03779529 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Olive oil
Description: Intervention includes dosage and amount of biophenols administered daily
Study NCT02242786 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation therapy
Study NCT03239652 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taiwan ACE Beads
Description: Similar with conventional Transcatheter Arterial chemo-embolization, radiologist use Taiwan ACE Beads instead of Gelfoam or polyvinyl alcohol.
Study NCT02266238 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DSA guided percutaneous balloon dilatation
Description: Under the guidance of DSA, balloon is introduced into the stenosis area, proper pressure is given to achieve balloon dilatation to expand the narrow AVF lumen.
Study NCT02266238 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided percutaneous balloon dilatation
Description: Under the guidance of ultrasound, balloon is introduced into the stenosis area, proper pressure is given to achieve balloon dilatation to expand the narrow AVF lumen.
Study NCT02266238 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical reconstruction
Description: Direct surgery to reconstruction the AVF lumen.
Study NCT03322202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Motivational Interviewing is a communication style that is intended to give patients the tools to reach goals through their own desires and actions.
Study NCT00856492 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00856492 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Given subcutaneously
Study NCT00856492 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pegfilgrastim
Description: Given subcutaneously
Study NCT00856492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00856492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given IV
Study NCT00856492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00856492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00856492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Description: Given IV
Study NCT00856492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Description: Given IV
Study NCT01111773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heated Lidocaine and Tetracaine Patch
Description: Patients will apply one lidocaine 70 mg and tetracaine 70 mg topical patch to the affected knee twice daily for approximately 14 days. Patches will be applied morning and evening (applications separated by approximately 8-10 hours).
Study NCT01938638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1143572
Study NCT01129557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Study NCT01129557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Study NCT03596957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolvaptan
Description: At baseline the tolvaptan dosing will start with daily morning and afternoon doses of 45 mg and 15 mg respectively, with weekly increases to 60 mg and 30 mg and then to 90 mg and 30 mg according to subject tolerability
Study NCT04119297 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: * Routine care was applied to the periorbital area by clinical nurses.~* Periorbital edema, upper and lower eyelid ecchymosis of the patients were evaluated on the 3rd and 9th hours after craniotomy, and on the 1st, 2nd and 3rd days (twice daily) using the Kara \& Gokalan's Scale
Study NCT04119297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold gel pack
Description: * Cold application was applied to the periorbital area for 20 minutes per hour beginning 3rd hour following craniotomy, except from 10pm-7 am, and for three days using gel pack cooled to -14ºC.~* Periorbital edema, upper and lower eyelid ecchymosis of the patients were evaluated on the 3rd and 9th hours after craniotomy, and on the 1st, 2nd and 3rd days (twice daily) using the Kara \& Gokalan's Scale
Study NCT04119297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparinoids Topical Cream
Description: * Heparinoid cream was applied to the periorbital area once at 3rd and 9th hours following craniotomy, and 4 times daily in the following 3 days.~* Periorbital edema, upper and lower eyelid ecchymosis of the patients were evaluated on the 3rd and 9th hours after craniotomy, and on the 1st, 2nd and 3rd days (twice daily) using the Kara \& Gokalan's Scale